IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
30.46
-1.63 (-5.08%)
Mar 27, 2026, 4:00 PM EDT - Market closed
IDEAYA Biosciences Stock Forecast
Stock Price Forecast
The 14 analysts that cover IDEAYA Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $51.21, which forecasts a 68.12% increase in the stock price over the next year. The lowest target is $30 and the highest is $79.
Price Target: $51.21 (+68.12%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 19, 2026.
Analyst Ratings
The average analyst rating for IDEAYA Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 6 | 6 |
| Buy | 11 | 9 | 9 | 8 | 9 | 9 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 14 | 14 | 14 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $64 → $65 | Strong Buy | Maintains | $64 → $65 | +113.39% | Feb 19, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $49 | Buy | Reiterates | $49 | +60.87% | Feb 18, 2026 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +64.15% | Feb 18, 2026 |
| Wedbush | Wedbush | Buy Maintains $49 → $52 | Buy | Maintains | $49 → $52 | +70.72% | Feb 18, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $41 → $45 | Buy | Maintains | $41 → $45 | +47.73% | Jan 21, 2026 |
Financial Forecast
Revenue This Year
40.60M
from 218.71M
Decreased by -81.43%
Revenue Next Year
118.19M
from 40.60M
Increased by 191.08%
EPS This Year
-3.98
from -1.28
EPS Next Year
-3.67
from -3.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 97.0M | 190.0M | |||
| Avg | 40.6M | 118.2M | |||
| Low | n/a | 45.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -55.7% | 367.8% | |||
| Avg | -81.4% | 191.1% | |||
| Low | - | 11.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.15 | -2.09 | |||
| Avg | -3.98 | -3.67 | |||
| Low | -4.60 | -4.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.